Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676167 | 1.00 | KMT2A (0.53) | KMT2AEPHX2CASP3FABP5F10 | |
| SCHEMBL6356317 | 0.80 | KMT2A (0.55) | KMT2AEPHX2CASP3PIN1MDM4 | |
| SCHEMBL13613350 | 0.76 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL4675533 | 0.74 | KMT2A (0.46) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL402111 | 0.73 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL15976511 | 0.73 | KMT2A (0.49) | KMT2AEPHX2CASP3FABP5F10 | |
| SCHEMBL3757636 | 0.73 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL7113144 | 0.72 | KMT2A (0.75) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3699996 | 0.71 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL4225816 | 0.71 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532134-B1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | EP | claimed |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | claimed |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | KMT2A 4026/4885EPHX2 1866/4885CASP3 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.